JBJutta Beier

Jutta Beier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jutta Beier has a total of 425 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Versorgungsforschung bei niedergelassenen Pneumologinnen und Pneumologen

    by Jutta Beier, Andrea Patzelt-Bath

    Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide. In recent years, both clinical guidelines and therapeutic options have evolved significantly. The aim of the DELFIN COPD 2 study (Deutsche Expert*innenbefragung: Leitlinien, Fakten, Informationen, Nutzereinschätzungen zur COPD 2), was to provide an up-to-date overview of outpatient care for COPD patients led by pulmonologists in Germany. As part of a nationwide cross-sectional survey, 377 office-based pulmonologists were interviewed using a standardised questionnaire between March and October 2024. Data were analysed descriptively.The results show that fixed combinations of long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) are commonly used as the preferred initial therapy in clinical practice. Many pulmonologists consider twice-daily inhalation beneficial, particularly in cases of evening and night-time symptoms. The majority of respondents observe the circadian pattern of COPD symptoms. They attribute this to a combination of physiological changes, waning medication effects and insufficient nocturnal ventilation. International recommendations, especially those from the Global Initiative for Chronic Obstructive Lung Disease (GOLD), play a key role in therapeutic decision-making, whereas economic factors, such as rebate contracts with health insurance providers, are less influential. Correct inhaler use is typically demonstrated by practice staff. Two-thirds of respondents offer smoking cessation support and half use digital tools to assist with patient care.DELFIN COPD 2 highlights the typical challenges of managing COPD in an outpatient setting, such as underutilisation of digital support options. Key elements of future COPD care include consistent smoking cessation efforts, personalised treatment strategies and greater integration of digital health tools.

  • Open Access

    Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial

    by Jutta Beier, Henrik Watz, Zuzana Diamant, Jens M. Hohlfeld, Dave Singh, Pascale Pinot, Ieuan Jones, Hanns-Christian Tillmann

    Once-daily asthma treatment should prevent night-time deterioration, irrespective of the time of dosing. IND/GLY/MF, a fixed-dose combination of inhaled indacaterol acetate (IND, long-acting β2-agonist (LABA)), glycopyrronium bromide (GLY, long-acting muscarinic antagonist) and mometasone furoate (MF, inhaled corticosteroid (ICS)) delivered by Breezhaler, is indicated in adult asthma patients inadequately controlled on LABA/ICS.A randomised, double-blind, placebo-controlled, three-period, crossover, phase II study was performed to investigate the bronchodilator effect of IND/GLY/MF (150/50/80 μg) dosed morning and eveningversusplacebo in patients with mild-moderate asthma. The primary end-point was weighted mean forced expiratory volume in 1 s (FEV1) over 24 h following 14 days of IND/GLY/MF dosed a.m. and p.m.versusplacebo. Secondary end-points included the effect of dosing time on peak expiratory flow (PEF) and safety/tolerability.Of 37 randomised patients (age 18–72 years; 21 male, 16 female) 34 completed all three treatment periods. At screening, median (range) pre-bronchodilator FEV1was 75.8% (60–96%). Patients were using stable low- (83.8%) or medium-dose (16.2%) ICS. Morning and evening dosing of IND/GLY/MF improved FEV1(area under the curve from 0 to 24 h) by 610 mL (90% CI 538–681 mL) and 615 mL (90% CI 544–687 mL), respectively,versusplacebo. Mean PEF over 14 days increased by 70.7 L·min−1(90% CI 60.5–80.9 L·min−1) following a.m. dosing, and by 59.7 L·min−1(90% CI 49.5–69.9 L·min−1) following p.m. dosing of IND/GLY/MFversusplacebo. IND/GLY/MF demonstrated a safety profile comparable with placebo.Once-daily inhaled IND/GLY/MF was well tolerated and provided sustained lung function improvements over 24 h, irrespective of a.m. or p.m. dosing, in patients with mild–moderate asthma.


  • Open Access

    Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial

    by Mary N. Brown, Rainard Fuhr, Jutta Beier, Hong-Lin Su, Yingxue Chen, Henrik Forsman, Ulrika Wählby Hamrén, Helen Jackson, Ajay Aggarwal

    Inhaled corticosteroids reduce inflammation in asthma but chronic use may cause adverse effects. AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, has the potential of an improved risk-benefit profile. We investigated the safety and efficacy of AZD7594 in asthma. This phase 2a multi-center, randomized, double-blind, placebo-controlled crossover study enrolled adults with asthma aged 18 to 75 years. Patients were treated with budesonide 200 μg twice daily for 2–3 3 weeks (run in part one). If controlled, as demonstrated by an asthma control questionnaire-5 score of < 1.5, patients entered a three-week run-in (part two) where they received a short acting bronchodilator alone. Thereafter, patients with a fractional exhaled nitric oxide (FENO) ≥25 ppb and pre-dose FEV1 40 to 90% predicted were randomized to one of nine treatment sequences. Each patient received placebo and two of three dose levels of AZD7594 (58, 250, 800 μg) once daily via inhalation, in 14-day treatment periods, separated by three-week washout periods. The primary endpoint was the change from baseline in morning trough FEV1 versus placebo on day 15. Secondary endpoints included measures of airway inflammation and asthma control. Fifty-four patients were randomized and received at least 1 dose of treatment, 48 patients completed the study. Overall 52 patients received placebo, 34 received AZD7594 58 μg, 34 received AZD7594 250 μg, and 34 received AZD7594 800 μg. AZD7594 800 μg demonstrated a significant improvement in Day 15 morning trough FEV1versus placebo (LS means difference 0.148 L 95% CI 0.035–0.261, p = 0.011), with a dose-dependent response seen in the 250 μg (0.076 L -0·036–0·188, p = 0.183) and 58 μg (0·027 L -0·086–0·140, p = 0.683). All secondary endpoints showed statistically significant improvement at the 800 μg dose. All doses demonstrated a significant reduction in FENO at day 15 p < 0.01. No statistically significant difference in plasma cortisol level was observed between AZD7594 and placebo at any dose. AZD7594 was considered safe and well tolerated. Two-week treatment with AZD7594 demonstrated a favorable risk-benefit profile in patients with mild to moderate asthma. Further clinical studies are needed to fully characterize AZD7594. ClinicalTrials.gov number NCT02479412 .


  • Open Access

    Efficacy, safety, and tolerability of once‐daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7‐day, crossover study

    by Jutta Beier, Rainard Fuhr, Beatriz Seoane, Eric Massana, Gonzalo de Miquel, Helena Pujol, Sandrine Ruiz

    Abediterol is a once‐daily, long‐acting β2‐adrenergic agonist in development for the treatment of asthma and chronic obstructive pulmonary disease. We assessed the efficacy, safety, and tolerability of three dose levels of abediterol, given once daily for 7 days in patients with stable, persistent asthma. This was an ascending‐dose, three‐period incomplete crossover study design investigating three dose levels of abediterol versus placebo (EudraCT No. 2008‐003732‐38). Twenty‐eight male patients (25–59 years) were randomized to one of four treatment sequences (1:1:1:1). Follow‐up was 7 days after final treatment. Spirometry was performed regularly up to 24 h postdose Day 1, up to 36 h postdose Day 7, and at follow‐up. Vital signs, 12‐lead electrocardiogram, and clinical laboratory tests were recorded throughout. Abediterol 2.5, 5, and 10 μg provided clinically and statistically significant improvements from baseline (predose, Day 1) in trough forced expiratory volume in 1 sec (FEV1) versus placebo on Day 7 (primary endpoint) of 334, 365, and 294 mL, respectively (all P < 0.01), and peak FEV1 versus placebo on Day 7 of 364 (P < 0.001), 403 (P < 0.001), and 375 mL (P < 0.01), respectively. Days 1 and 7 area under the curve (AUC) parameters within each abediterol group were similar for AUC0–6, AUC0–12, AUC0–24, and AUC12–24, with dose‐dependent effects observed on Day 1. Abediterol (2.5–10 μg) demonstrated a good safety and tolerability profile. Abediterol 2.5, 5, and 10 μg once daily achieved statistically and clinically significant improvements in pulmonary function versus placebo over 7 days and demonstrated a safety and tolerability profile comparable with placebo.


  • Open Access

    Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study

    by Jutta Beier, Robert Mroz, Anne-Marie Kirsten, Ferran Chuecos, Esther Garcia Gil

    Background: A previous Phase IIIb study (NCT01462929) in patients with moderate to severe COPD demonstrated that 6 weeks of treatment with aclidinium led to improvements in 24-hour bronchodilation comparable to those with tiotropium, and improvement of symptoms versus placebo. This post hoc analysis was performed to assess the effect of treatment in the symptomatic patient group participating in the study. Methods: Symptomatic patients (defined as those with Evaluating Respiratory Symptoms [E-RS™] in COPD baseline score ≥10 units) received aclidinium bromide 400 µg twice daily (BID), tiotropium 18 µg once daily (QD), or placebo, for 6 weeks. Lung function, COPD respiratory symptoms, and incidence of adverse events (AEs) were assessed. Results: In all, 277 symptomatic patients were included in this post hoc analysis. Aclidinium and tiotropium treatment improved forced expiratory volume in 1 second (FEV1) from baseline to week 6 at all time points over 24 hours versus placebo. In addition, improvements in FEV1 from baseline during the nighttime period were observed for aclidinium versus tiotropium on day 1 (aclidinium 157 mL, tiotropium 67 mL; PP1 from baseline versus placebo and tiotropium at day 1 (aclidinium 136 mL, tiotropium 68 mL; PP Conclusion: In this post hoc analysis of symptomatic patients with moderate to severe COPD, aclidinium 400 µg BID provided additional improvements compared with tiotropium 18 µg QD in: 1) bronchodilation, particularly during the nighttime, 2) daily COPD symptoms (E-RS), 3) early-morning and nighttime symptoms, and 4) early-morning limitation of activity.


  • The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma

    by Veit J. Erpenbeck, Todor A. Popov, David Miller, Steven F. Weinstein, Sheldon Spector, Baldur Magnusson, Wande Osuntokun, Paul Goldsmith, Markus Weiss, Jutta Beier


  • Open Access

    Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD

    by Jutta Beier, Helena Pujol, Beatriz Seoane, Eulalia Jimenez, Carol Astbury, Eric Massana, Sandrine Ruiz, Gonzalo de Miquel

    Abediterol is a novel, once-daily long-acting β2-agonist in development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with an anti-inflammatory agent. This Phase IIa, randomised, double-blind, crossover study investigated the bronchodilation, safety, tolerability and pharmacokinetics of abediterol in patients with moderate to severe COPD. Seventy patients (aged ≥40 years, Global initiative for chronic Obstructive Lung Disease Stage II/III) were randomised (1:1:1:1:1:1) to single doses of abediterol 0.625, 2.5, 5 or 10 μg, indacaterol 150 μg or placebo. Spirometry was performed up to 36 h post-dose. Pharmacokinetics were assessed in a subset of patients (N = 20). Safety and tolerability were evaluated throughout the study. Abediterol (all doses) significantly improved change from baseline in trough forced expiratory volume in 1 s (FEV1) compared with placebo (0.102, 0.203, 0.233 and 0.259 L for abediterol 0.625, 2.5, 5 and 10 μg, respectively; all p < 0.0001; primary endpoint). Abediterol 2.5, 5 and 10 μg significantly improved trough FEV1 compared with indacaterol 150 μg (0.092, 0.122 and 0.148 L, respectively; all p < 0.0001). Improvements in bronchodilation were maintained at all time points post-dose versus placebo (all abediterol doses) and from 15 or 30 min post-dose versus indacaterol 150 μg with abediterol 2.5, 5 and 10 μg (all p < 0.05). Abediterol had low systemic exposure; incidence of treatment-emergent adverse events was similar between treatment groups. All doses of abediterol (0.625–10 μg) provided clinically and statistically significant, dose-dependent improvements in bronchodilation versus placebo, and abediterol 2.5, 5 and 10 μg gave significant improvements versus indacaterol. All doses of abediterol were safe and well tolerated in patients with COPD. Clinicaltrials.gov NCT01425814 . Registered 29 August 2011.


  • Overall safety and cardiovascular safety of fixed-dose combination of aclidinium/formoterol compared to salmeterol/fluticasone in patients with COPD

    by J Beier, C Vogelmeier, R Mroz, S Pascual, Rm Segarra, A Lei, G de Miquel

    Hintergrund: Die zweimal tägliche (BID) Gabe der Fixdosis-Kombination aus Aclidiniumbromid/Formoterolfumarat 400/12 µg ist in Europa zur Behandlung von COPD zugelassen. Ziel: Bewertung der Gesamtsicherheit und der kardiovaskulären (KV) Sicherheit von Aclidinium/Formoterol 400/12 µg gegenüber Salmeterol/Fluticasonpropionat 50/500 µg bei Patienten mit COPD. Methoden: Die Sicherheitsdaten aus einer 24-wöchigen, randomisierten, doppelblinden Phase-IIIb-Studie über Aclidinium/Formoterol 400/12 µg BID oder Salmeterol/Fluticason 50/500 µg BID an Patienten mit COPD (NCT01908140) wurden ausgewertet. Unerwünschte Ereignisse (UE), einschließlich kardialer, zerebrovaskulärer und schwerwiegender UE (SUE), wurden überwacht. Laboruntersuchungen und Elektrokardiogramme (EKGs) wurden aufgezeichnet. Ergebnisse: Die Sicherheitspopulation umfasste 933 Patienten: mittleres Alter 63,4 Jahre, 65,1% männlich. Bei der Erfassung der Ausgangswerte litten 52,8% unter hypertensiven Krankheiten, 11,8% unter Diabetes und 21,8% unter Herzerkrankungen. Die Häufigkeit von UE und SUE war in beiden Gruppen vergleichbar (Tabelle). Die Häufigkeit von kardialen und zerebrovaskulären UE war in beiden Gruppen gering (Tabelle). Durch inhalative Corticosteroide (ICS) bedingte UE traten bei Patienten, die eine Behandlung mit Salmeterol/Fluticason erhielten, häufiger auf als in der Aclidinium/Formoterol-Gruppe (Tabelle). Darüber hinaus war die Gesamthäufigkeit von Anticholinergika-bedingten UE in der Aclidinium/Formoterol-Gruppe nicht höher als in der Salmeterol/Fluticason-Gruppe (Tabelle). Die Labor- und EKG-Ergebnisse waren in beiden Gruppen vergleichbar. Schlussfolgerungen: Aclidinium/Formoterol 400/12 µg und Salmeterol/Fluticason 50/500 µg wurden von den COPD-Patienten gut vertragen. Kardiovaskuläre UE traten selten auf. Finanzierung Diese Studie wurde von Almirall S.A., Barcelona, Spanien, finanziert. Die Unterstützung beim Medical Writing erfolgte durch Richard Knight von Complete Medical Communications und wurde von AstraZeneca PLC, Barcelona, Spanien, finanziert.

  • Results of three Phase II trials with the long-acting β2-adrenergic agonist (LABA) abediterol in patients with persistent asthma

    by J Beier, D Singh, R Fuhr, S Ruiz, B Seoane, E Massana, E Jimenez, H Pujol, C Astbury, G de Miquel

    Introduction: Efficacy and safety of abediterol (LAS100977), a novel LABA in development as a fixed dose combination with an inhaled corticosteroid for the treatment of asthma and COPD, were investigated in 3 Phase II trials in patients with persistent, stable asthma. Methods: Randomized, double-blind, placebo-controlled, crossover designs were used. Single doses (dose range: 0.313 to 25 µg) of abediterol were administered in the morning via Cyclohaler® (Study 1 and 2) or Genuair® (Study 3). In studies 1 and 3, active comparators (salmeterol and salbutamol, respectively) were used. Change from baseline in FEV1 was assessed and treatment emergent adverse events (TEAEs) were recorded. Results: Abediterol, in all doses, produced rapid (≤ 15 minutes post-dose), sustained, clinically significant bronchodilation and a significant higher trough FEV1 versus placebo (table). TEAEs were consistent with the drug class and most were mild to moderate in intensity. Conclusions: Abediterol effectively improved bronchodilation in patients with asthma compared with placebo and was safe and well tolerated.

  • Open Access

    Longitudinal measurement of airway inflammation over one year in children and adults with intermittent asthma

    by Frauke Pedersen, Olaf Holz, Frank Kanniess, Stefan Zielen, Johannes Schulze, Adrian Gillissen, Andrea von Berg, Dietrich Berdel, Jutta Beier, Kai Beeh, et al.

    Asthma is an inflammatory disease of the airways, but in clinical practice inflammation is rarely monitored. The aim of this study was to assess the level of airway inflammation in steroid naïve adult and pediatric patients with intermittent asthma over one year.